Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
CA244-0001
Advanced Solid Tumors Phase I/II
- 9.6 weeks
- 1st site activated in Canada and 2nd site activated worldwide
CA244-0001
Advanced Solid Tumors Phase I/II
- 12.4 weeks
- 2nd site activated in Canada and 3rd site activated worldwide
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
- 8 weeks
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
- 11.6 weeks
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
- 12 weeks
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
- 16.4 weeks
- 1st site activated in Canada
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
- 17 weeks
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
- 22 weeks
CAAA601A42101
Lung Cancer Phase I/II
- 13.2 weeks
- 1st site activated in Canada
CAAA601A42101
Lung Cancer Phase I/II
- 14 weeks
CESP359A12101
Prostate Cancer Phase I
- 9.8 weeks
CGCJ904A12101
Solid Tumors Phase I
- 7.2 weeks
- 1st site activated in Canada
CJSB462B12201
Prostate Cancer Phase II
- 8.4 weeks
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 7.6 weeks
- Co-1st site activated in Canada
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 12.4 weeks
CLOU064P12301 (REMASTER)
Secondary progressive multiple sclerosis Phase III
- 15.4 weeks
CMAS825J12201
Still's Disease Phase II
- 8.4 weeks
- 2nd site activated worldwide
CMAS825J12201
Still's Disease Phase II
- 10.2 weeks
- 3rd site activated worldwide
CO45042 (KRAScendo-2)
Oncology (Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer) Phase III
- 9.2 weeks
CO45042 (KRAScendo-2)
Oncology (Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer) Phase III
- 9.6 weeks
CO45042 (KRAScendo-2)
Advanced or metastatic non-squamous non Small cell lung cancer Phase III
- 9.2 weeks
- Co-1st site activated in Canada
CO45042 (KRAScendo-2)
Advanced or metastatic non-squamous non Small cell lung cancer Phase III
- 9.6 weeks
CO45042 (KRAScendo-2)
Advanced or metastatic non-squamous non Small cell lung cancer Phase III
- 8 weeks
CO45813
Oncology Phase II
- 10 weeks
CO45813
Oncology Phase II
- 13.4 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
- 7.8 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
- 11.4 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
- 14.6 weeks